Table II.
Summary table of ORs for association between six PPARA polymorphisms and breast cancer risk by menopausal status in LIBCSP
| Genotype | Genotypea | MAFb | Cases, n (%)c | Controls, n (%)c | P for trendd | ORe | 95% CI |
| All women | |||||||
| rs135542 | AA | 0.224 | 602 (59.4) | 634 (59.3) | 0.90 | 1.00 | |
| AG | 370 (36.5) | 392 (36.7) | 1.01 | 0.84, 1.21 | |||
| GG | 41 (4.1) | 43 (4.0) | 1.01 | 0.65, 1.57 | |||
| AG + GG | 411 (40.6) | 435 (40.7) | 1.01 | 0.85, 1.21 | |||
| Total | 1013 | 1069 | |||||
| rs1800206 (L162V) | CC (L/L) | 0.054 | 927 (89.7) | 973 (89.7) | 0.72 | 1.00 | |
| CG (L/V) | 100 (9.7) | 109 (10.1) | 0.97 | 0.73, 1.30 | |||
| GG (V/V) | 7 (0.7) | 3 (0.3) | 2.44 | 0.63, 9.50 | |||
| L/V + V/V | 107 (10.4) | 112 (10.3) | 1.01 | 0.76, 1.34 | |||
| Total | 1034 | 1085 | |||||
| rs4253623 | AA | 0.123 | 811 (77.5) | 849 (77.0) | 0.77 | 1.00 | |
| AG | 218 (20.8) | 236 (21.4) | 0.97 | 0.79, 1.19 | |||
| GG | 17 (1.6) | 17 (1.5) | 0.98 | 0.49, 1.93 | |||
| AG + GG | 235 (22.5) | 253 (23.0) | 0.97 | 0.79, 1.19 | |||
| Total | 1046 | 1102 | |||||
| rs4253699 | TT | 0.220 | 624 (60.0) | 671 (61.5) | 0.52 | 1.00 | |
| CT | 358 (34.4) | 362 (33.2) | 1.06 | 0.88, 1.27 | |||
| CC | 58 (5.6) | 59 (5.4) | 1.07 | 0.73, 1.57 | |||
| CT + CC | 416 (40.0) | 421 (38.6) | 1.06 | 0.89, 1.27 | |||
| Total | 1048 | 1092 | |||||
| rs4253755 | GG | 0.120 | 803 (76.5) | 845 (77.4) | 0.64 | 1.00 | |
| AG | 231 (22.0) | 231 (21.2) | 1.05 | 0.85, 1.29 | |||
| AA | 16 (1.5) | 16 (1.5) | 1.05 | 0.52, 2.12 | |||
| AG + AA | 247 (23.5) | 247 (22.6) | 1.05 | 0.86, 1.29 | |||
| Total | 1050 | 1092 | |||||
| rs4253760 | TT | 0.186 | 675 (66.2) | 713 (67.2) | 0.41 | 1.00 | |
| GT | 293 (28.7) | 302 (28.5) | 1.02 | 0.84, 1.24 | |||
| GG | 52 (5.1) | 46 (4.3) | 1.25 | 0.83, 1.87 | |||
| GT + GG | 345 (33.8) | 348 (32.8) | 1.05 | 0.88, 1.26 | |||
| Total | 1020 | 1061 | |||||
| Postmenopausal | |||||||
| rs135542 | AA | 0.220 | 395 (59.0) | 397 (60.0) | 0.61 | 1.00 | |
| AG | 247 (36.9) | 239 (36.1) | 1.07 | 0.85, 1.35 | |||
| GG | 27 (4.0) | 26 (3.9) | 1.04 | 0.59, 1.81 | |||
| AG + GG | 274 (41.0) | 265 (40.0) | 1.07 | 0.86, 1.33 | |||
| Total | 669 | 662 | |||||
| rs1800206 (L162V) | CC (L/L) | 0.052 | 610 (89.3) | 609 (89.7) | 0.51 | 1.00 | |
| CG (L/V) | 68 (10.0) | 69 (10.2) | 1.01 | 0.71, 1.44 | |||
| GG (V/V) | 5 (0.7) | 1 (0.2) | 5.07 | 0.59, 43.71 | |||
| L/V + V/V | 73 (10.7) | 70 (10.3) | 1.06 | 0.75, 1.51 | |||
| Total | 673 | 679 | |||||
| rs4253623 | AA | 0.132 | 533 (77.4) | 522 (75.9) | 0.43 | 1.00 | |
| AG | 145 (21.0) | 150 (21.8) | 0.96 | 0.74, 1.24 | |||
| GG | 11 (1.6) | 16 (2.3) | 0.66 | 0.30, 1.45 | |||
| AG + GG | 156 (22.6) | 166 (24.1) | 0.93 | 0.72, 1.20 | |||
| Total | 689 | 688 | |||||
| rs4253699 | TT | 0.217 | 411 (59.8) | 425 (62.2) | 0.62 | 1.00 | |
| CT | 243 (35.4) | 220 (32.2) | 1.13 | 0.90, 1.42 | |||
| CC | 33 (4.8) | 38 (5.6) | 0.92 | 0.56, 1.49 | |||
| CT + CC | 276 (40.2) | 258 (37.8) | 1.10 | 0.88, 1.37 | |||
| Total | 687 | 683 | |||||
| rs4253755 | GG | 0.113 | 532 (76.3) | 535 (78.8) | 0.29 | 1.00 | |
| AG | 153 (22.0) | 135 (19.9) | 1.12 | 0.86, 1.46 | |||
| AA | 12 (1.7) | 9 (1.3) | 1.36 | 0.57, 3.27 | |||
| AG + AA | 165 (23.7) | 144 (21.2) | 1.14 | 0.88, 1.47 | |||
| Total | 697 | 679 | |||||
| rs4253760 | TT | 0.168 | 441 (65.0) | 454 (69.6) | 0.02 | 1.00 | |
| GT | 199 (29.4) | 177 (27.2) | 1.14 | 0.90, 1.46 | |||
| GG | 38 (5.6) | 21 (3.2) | 1.97 | 1.14, 3.43 | |||
| GT + GG | 237 (35.0) | 198 (30.4) | 1.23 | 0.98, 1.55 | |||
| Total | 678 | 652 |
a
The combined heterozygotes and rare homozygotes were modeled separately and compared with common homozygotes.
b
Minor allele frequency (MAF) calculated among controls.
c
May not add up to 100.0 due to rounding.
d
P-value for trend was calculated by coding each genotype as 0, 1 or 2 based on the number of risk alleles.
e
Adjusted for age, measured in 5-year intervals.